Equity Overview
Price & Market Data
Price: $7.90
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $48,883,676
Daily Volume: 0
Performance Metrics
1 Week: 20.43%
1 Month: 13.18%
3 Months: -6.06%
6 Months: -21.55%
1 Year: 56.44%
YTD: -15.24%
Company Details
Employees: 82
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.